Physician profile
Roma Anand
NPI 1356845622
$2,080.70
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $249 · 2022: $874 · 2023: $904 · 2024: $54.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $244.67 | 2021-2023 | Dupixent |
| Harmony Biosciences LLC | $237.64 | 2021-2023 | Wakix |
| Astrazeneca Pharmaceuticals LP | $217.01 | 2021-2023 | Tezspire, Breztri |
| Glaxosmithkline, LLC. | $206.36 | 2021-2023 | Trelegy Ellipta, Arexvy, Nucala |
| Jazz Pharmaceuticals INC. | $196.73 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.85 | 2021-2023 | Ofev |
| Sun Pharmaceutical Industries INC. | $124.14 | 2023 | Cequa |
| Grifols USA, LLC | $93.57 | 2022-2023 | Prolastin-C Liquid |
| Genzyme Corporation | $91.65 | 2022-2023 | |
| Merz North America, INC. | $89.30 | 2023 | Xeomin |
| Insmed, INC. | $74.66 | 2022-2023 | Arikayce |
| Tarsus Pharmaceuticals, INC. | $54.35 | 2024 | Xdemvy |
| Inspire Medical Systems, INC. | $46.04 | 2023 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $31.93 | 2023 | Glassia |
| Mallinckrodt Hospital Products INC. | $28.77 | 2023 | Acthar |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $28.07 | 2022 | |
| Baxter Healthcare | $22.43 | 2022 | |
| Vanda Pharmaceuticals INC. | $21.45 | 2023 | Hetlioz |
| Teva Pharmaceuticals USA, INC. | $18.87 | 2022 | |
| Mylan Specialty L.P. | $17.84 | 2022 | |
| Merck Sharp & Dohme LLC | $16.47 | 2023 | |
| Phadia US INC. | $12.89 | 2022 | |
| Inogen, INC. | $11.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roma Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.